UNION therapeutics Denmark

09.01.2023 - 16:38:02

UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis

Primary endpoint at week 16 was met for all three active doses of oral orismilast in moderate to severe patients with psoriasis. Statistical significance reached already at the first time point after 4 weeks of treatmentHigh potency supported by secondary endpoints, including PASI-90 and PASI-100Results support the target product profile of a best-in-class PDE4 inhibitor and confirm the well-established favorable safety profile of PDE4 inhibitionOral orismilast is also in development for treatment of atopic dermatitis (AD) and hidradenitis suppurativa (HS)View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-announces-positive-topline-results-from-the-iasos-phase-2b-study-of-oral-orismilast-in-patients-with-moderate-to-severe-psoriasis-301716687.html

@ prnewswire.co.uk